Involving children and young people in paediatric research priority setting: a narrative review

Laura Postma 1,2, Malou L Luchtenberg,2,3 A A Eduard Verhagen,2,4 Els L Maeckelberghe2

ABSTRACT

Objective The objective of this study is twofold: first, to describe the methods used when involving children and young people (CYP) in developing a paediatric research agenda and, second, to evaluate how the existing literature describes the impact of involving CYP. We distinguish three forms of impact: impact on the research agenda (focused impact), impact on researchers and CYP (diffuse impact) and impact on future research (research impact).

Design A narrative review of MEDLINE, PsycINFO, Web of Science and Google Scholar was conducted from October 2016 to January 2022. The included studies involved at least one CYP in developing a research agenda and were published in English.

Results 22 studies were included: the CYP involved were aged between 6 years and 25 years. Little variation was found in the methods used to involve them. The methods used were James Lind Alliance (JLA) approach (n=16), focus groups (n=2), workshop (n=2), research prioritisation by affected communities (n=1) and combined methods (n=1). Impact was rarely described: focused impact in nine studies, diffuse impact in zero studies and research impact in three studies.

Conclusion This study concludes that the JLA approach is most frequently used to involve CYP and that all methods used to involve them are rarely evaluated. It also concludes that the reported impact of involving CYPs is incomplete. This study implies that to convince sceptical researchers of the benefits of involving CYPs and to justify the costs, more attention should be paid to reporting these impacts.

INTRODUCTION

The idea that children should be treated as passive subjects in research is changing. They are more and more involved as active agents.1 The involvement of children is now recognised as a best practice and is an essential requirement for paediatric research funding allocation by funders in the UK, Australia, the USA and the Netherlands.1,2 Children should be involved in every phase of the research, starting with what research should be about, in so-called research agendas. Paediatric research agendas used to be predominantly developed by professionals and researchers.3 Increasing evidence illustrates that research questions prioritised by professionals may not be aligned to those experiencing the disease.4 At worst, this results in limited research money being spent on research that is not important to patients, and money is wasted.5 This raised a call for collaboration with children and young people (CYP) as equal partners to develop research agendas.

Thus far, the involvement of CYP in developing research agendas appears to be limited. Few studies purely include CYP in developing those agendas. More often, adults act as a proxy for CYP’s views.5 A systematic review by Odgers and colleagues published in 2017 showed that 25% of studies reported some parental or caregiver involvement. Only in 5% of the studies were children involved directly.6 This is partly explained because there is no agreement on what might constitute best practice for involving CYP in developing a research agenda.7 Moreover, the involvement of CYP may bring age-specific barriers and challenges such as increased workload, unknown impact on the research agenda and power imbalances.2

Efforts to develop engaging and developmentally appropriate strategies that involve CYP in developing a research agenda are lacking. The most well-known example is
the James Lind Alliance (JLA) method. The JLA unites patients, carers and clinicians to identify and prioritise the top 10 unanswered research questions in so-called priority setting partnerships (PSPs). Odgers and colleagues question the extent to which the JLA method may be well suited to involve CYP, although they do not clarify this claim. Previous studies have not dealt with identifying what methods are well suited to involve CYP in PSPs.

One of the most significant discussions about involving CYP is that the impact of their involvement is not clear. Reasons for assessing this are numerous: to improve the involvement of CYP, to convince sceptical researchers of its benefits, to reduce tokenistic involvement, to justify the cost of the involvement of CYP, and to increase funding for their involvement. Therefore, it is strongly recommended to conduct more research that critically examines this impact. We distinguish three forms of impact, of which the first two were described before.

1. The effect of the involvement of CYP on the research agenda (focused impact),
2. The effect of the involvement of CYP on researchers and CYP themselves (diffuse impact) and
3. What is reported on action plans for assessing the effect of the research agenda on future research (research impact).

Assessing these forms of impact may be challenging but documenting the contributions and incorporations of these contributions into the research priority setting may be feasible and would be welcomed by many contributors.

This paper has two key aims. First, we will identify the methods used to involve CYP in formulating a research agenda and perform a first exploration on the evaluation of these methods. Second, the study aims to assess what is reported about the impact of involving CYP in research priority setting.

### METHODS

We conducted a narrative review to gain a qualitative perspective on the methods used to involve CYP in developing a research agenda and the reported impact of this involvement.

#### Search strategy

The research team cocreated the literature search strategy in collaboration with an information librarian. We used the Medical Subject Headings and text words for 'children', 'priority setting partnerships' and 'research agenda'. Online supplemental file 1 provides more details about the search strategy. Each search term within the three categories were combined with the Boolean operator "OR" and the three different categories were combined with the Boolean operator "AND". Databases searched were MEDLINE, EBSCOhost, Web of Science, Google Scholar and the JLA website. The included articles were uploaded in the programme Rayyan QCRI (Qatar Computing Research Institute (Data Analytics), Doha, Qatar) and duplicates were removed.

#### Study selection

The research team specified the inclusion criteria after a thorough consultation. Articles were included in this review if developing a paediatric research agenda with the involvement of at least one CYP aged below 18 years was reported and if the articles were written in English and were published between October 2016 and March 2022.
Table 1  Included studies that used the JLA approach

| Authors (year) | Title | Topic | Children/young people | Method | Country |
|---------------|-------|-------|-----------------------|--------|---------|
| Obeid et al\textsuperscript{16} (2020) | Cocreating research priorities for anorexia nervosa: the Canadian Eating Disorder Priority Setting Partnership | Anorexia nervosa | 15–25 years: steering committee (n=1), first survey (n=33), workshop (n=3) | James Lind Alliance | Canada |
| Knight et al\textsuperscript{27} (2016) | Defining priorities for future research: results of the UK Kidney Transplant Priority Setting Partnership | Kidney transplantation | <18 years: (n=1) and 18–24 years (n=2) in prioritisation | James Lind Alliance | UK |
| Verwoerd et al\textsuperscript{17} (2021) | Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritis | JIA | 10–15 years: focus group meetings with children with JIA; focus groups are implemented especially for children | James Lind Alliance | The Netherlands |
| Grant et al\textsuperscript{18} (2019) | Engaging patients and caregivers in research for paediatric inflammatory bowel disease: top 10 research priorities | Paediatric Inflammatory bowel disease | 111 patients with IBD, ages between 10 and 85 years included in solicitation survey and 25 patients with IBD, ages between 11 and 35 | James Lind Alliance | Canada |
| Fackrell et al\textsuperscript{19} (2019) | Identifying and prioritising unanswered research questions for people with hyperacusis: James Lind Alliance hyperacusis priority setting partnership | Hyperacusis | 0–4 years; prioritisation (n=4), 10–20: identification (n=7), prioritisation (n=11) | James Lind Alliance | UK |
| Morris et al\textsuperscript{36} (2018) | Identifying primary care patient safety research priorities in the UK: a James Lind Alliance priority setting partnership | Primary care patient safety | 16–24 years: first survey (n=4) and second survey (n=5) | JLA | UK |
| Rankin et al\textsuperscript{37} (2020) | Identifying priorities for physiotherapy research in the UK: the James Lind Alliance physiotherapy priority setting partnership | Physiotherapy | Identification 9–88 years, prioritisation 17–89 years | JLA | UK |
| Hollis et al\textsuperscript{31} (2018) | Identifying research priorities for digital technology in mental healthcare: results of the James Lind Alliance priority setting partnership | Digital technology in mental healthcare | Identification <15 (n=6) and 16–24 years (n=63), prioritisation <15 years (n=3) and 16–24 years (n=62) | JLA | UK |
| Lim et al\textsuperscript{38} (2019) | Joint production of research priorities to improve the lives of those with childhood onset conditions that impair learning: the James Lind Alliance priority setting partnership for learning difficulties | Childhood conditions that impair learning | <25 years: (n=41) in prioritisation and (n=5) in the final workshop | JLA | UK |
| Birnie et al\textsuperscript{22} (2019) | Partnering for pain: a priority setting partnership to identify patient-oriented research priorities for paediatric chronic pain in Canada | Paediatric chronic pain | <18 years: national survey (n=33), prioritisation (n=8) priority setting workshop (n=3) | JLA | Canada |
| Ismail et al\textsuperscript{30} (2021) | Research priorities and identification of a health-service delivery model for psoriasis form the UK psoriasis priority setting partnership | Psoriasis | Identification <16 years (n=7) and 17–24 years (n=33), prioritisation <16 (n=7) and 17–24 years (n=67) | JLA | UK |
| Peeks et al\textsuperscript{29} (2019) | Research priorities for liver glycogen storage disease: An international priority setting partnership with the James Lind Alliance | Liver glycogen storage disease | Median age 12 (n=unclear) | JLA | The Netherlands |
| Lam et al\textsuperscript{39} (2019) | Research priorities for the future health of multiples and their families: the Global Twins and Multiples Priority Setting Partnership | Health priorities for multiples and families | <20 years: (n=4) survey 1 and (n=1) survey 2 | JLA | UK |
| Aldiss et al\textsuperscript{23} (2019) | Research priorities for young people with cancer: a UK priority setting partnership with the James Lind Alliance | Young people with cancer | 13–24 years: first survey (n=108), second survey (n=58), workshop (n=7), steering group (n=5) | JLA | UK |
| Vella-Baldacchino et al\textsuperscript{41} (2019) | Research priorities in children requiring elective surgery for conditions affecting the lower limbs: a James Lind Alliance priority setting partnership | Children requiring elective surgery for the lower limbs | Workshop (n=4), no age specified | JLA | UK |
| Finer et al\textsuperscript{28} (2018) | Setting the top 10 research priorities to improve the health of people with type 2 diabetes: a diabetes UK James Lind Alliance Priority Setting Partnership | Diabetes type 2 | First survey <20 years (n=5) | JLA | UK |

IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis; JLA, James Lind Alliance.

(to add more research agendas that have been developed with CYP to the four already identified by Odgers and colleagues).\textsuperscript{6} For the inclusion, we have chosen a three-step approach: (1) the first author screened the title and abstracts of 557 articles; (2) all articles for which it was unclear whether they should be included were intensively discussed with the last author; moreover, the articles that were already included were discussed in detail; (3) in the final step, the inclusion was discussed with the research team. The same three-step approach was chosen for the inclusion of the 89 full-text articles.

**Data analysis**

A narrative synthesis was performed. To systematically describe data from the included studies, two data extraction forms in Microsoft Excel were developed. Descriptive information of the studies (eg, title, authors and method used to involve CYP) were reported on the first
data extraction form. The second form was developed to chart data on the age and the number of the CYP involved, the phase of the involvement and the impact of the involvement. To assess the impact of the research priority setting, we divided impact into three forms: focused impact, diffuse impact and research impact. The data were extracted by LP and discussed with the research team.

**Checklist**

We used the 32-item checklist developed by Odgers and colleagues to assess the transparency of reporting of research priority setting. They extracted items from good practice principles to develop the checklist. Another frequently used checklist, the Guidance for Reporting Involvement of Patients and Public checklist (GRIIPP2), was developed to help improve the quality, consistency and transparency of reporting patient and public involvement in research. The checklist of Odgers differed from the GRIIPP2 checklist in that it was developed to assess the reporting of research priority setting specific. Therefore, we decided to use the checklist of Odgers instead of the GRIIPP2 checklist.

The original checklist of Odgers was not developed to specifically assess the reporting on developing a research agenda together with CYP. Therefore, we added three items to make sure the checklist covers important aspects of involving CYP. Next, the items will be further explained. The first item, ‘describes the method used to involve CYP in developing a research agenda’, was added to the list because we agree with Flynn and colleagues that appropriate strategies that involve CYP are lacking. The second and third items were added to the list to assess different forms of impact: ‘describe the impact of the involvement of CYP on the research agenda’ (focused impact) and ‘describe the impact of the research priority setting on the participants (diffuse impact). We rephrased the original item 29: ‘describe how impact will be measured’ as ‘describe how the impact of the research agenda on future research will be measured’ (online supplemental file 5).

**RESULTS**

Twenty-two studies were included in this review (figure 1). Most of the studies were conducted in the UK (n=13) (online supplemental file 2 and figure 1). The CYP involved were aged between 6 and 25 years. Seventeen studies involved children below the age of 18, and 2 studies did not report the age of the CYP involved. The number of the CYP involved in the included studies ranged from 1 to 108. Four studies did not report the number of CYP involved (see tables 1 and 2).

**Checklist**

The transparency of reporting score was averaged across the studies. The scores of those included ranged from 11 to 27 items out of 36 items (online supplemental file...
3, figure 2). Strikingly, few studies reported the impact of the CYP on the agenda (n=9), the action plans for implementing priorities (n=8), the evaluation of the PSP (n=6), methods used to involve CYP (n=5) and how impact of the research agenda will be measured (n=3). No studies reported how the feedback was integrated

Table 3 Checklist of Odgers (adjusted)

| Context and scope | Yes | No |
|-------------------|-----|----|
| 1. Define geographical scope. | 9 16–23 25–36 | 24 |
| 2. Define health area or focus. | 9 16–36 | None |
| 3. Define end users of research. | 9 16–36 | None |
| 4. Define the target audience. | 17 20 26 35 | 9 16 18 19 21–25 27–34 36 |
| 5. Identify the research focus. | 9 16–36 | None |
| 6. Identify the type of research question. | 9 16 17 19–23 25–27 29–34 36 | 18 24 28 35 |
| 7. Define the time frame. | None | 9 16–36 |
| Governance and team | | |
| 8. Describe selection of the project leader/s and team. | 16 17 20 24 27–31 | 9 18 19 21–23 25 26 32–36 |
| 9. Describe the characteristics of the project leader/team. | 16 17 22 23 25 26 28–31 | 9 18–24 27 32–36 |
| 10. Training or experience in research priority setting. | 16–21 23–31 | 9 22 32–36 |
| Inclusion of stakeholders | | |
| 11. Define the inclusion criteria for stakeholder groups involved in the priority setting partnership. | 9 18 20 22 23 25 27 32–35 | 16 17 19 21 24 26 28–31 36 |
| 12. State the strategy or method for identifying and engaging. | 9 16–36 | None |
| 13. Indicate the number of participants and/or organisations involved. | 9 16–36 | None |
| 14. Describe the characteristics of stakeholders. | 9 16–23 25–36 | 24 |
| 15. Time investment of the stakeholders | 16 17 19 22–27 34–36 | 9 18 20 21 28–33 |
| 16. Reimbursement for participation | 9 22 33–35 | 16–21 23–32 36 |
| Identification and collection of research topics | | |
| 17. Describe methods for collecting all research topics or questions. | 9 16–36 | None |
| 18. Describe methods for collecting and/or categorising topics. | 9 18 19 21 23 27–29 31 33 35 | 16 17 20 22 24–26 30 32 34 36 |
| 19. Describe methods or reason for initial removal of topics or questions. | 16–23 25–30 | 9 24 31–36 |
| 20. Describe methods for refining research questions/topics. | 16 18–23 26 27 | 9 17 24 25 28–36 |
| 21. Cross-check to identify if research questions have been answered. | 16–21 23–27 29–31 36 | 9 22 28 32–35 |
| 22. Describe number of research questions/topics. | 16–31 33 35 36 | 9 32 34 |
| Prioritisation of research topics | | |
| 23. Describe specific methods to involve children | 9 17 18 25 26 | 16 19–24 27–36 |
| 24. Describe methods for prioritising or achieving consensus. | 9 16–31 33–36 | 32 |
| 25. Provide reasons for excluding research topics/questions. | 21 26–31 | 9 16–20 22–25 32–36 |
| Output | | |
| 26. Define specificity of research priorities. | 9 16 17 20–24 26 28–36 | 18 19 25 27 |
| Evaluation and feedback | | |
| 27. Describe how the research priorities exercise was evaluated. | 9 16 17 22 26 34 | 18–21 23–25 27–33 35 36 |
| 28. Describe how priorities were made accessible by stakeholders | 20 24 26–29 | 9 16–19 21–23 25 30–36 |
| 29. State how feedback was integrated. | None | 9 16–36 |
| Dissemination, translation and implementation | | |
| 30. Outline the strategy or action plans for implementing priorities. | 17 18 20 24 26 28 29 31 | 9 16 19 21–23 25 27 30 32–36 |
| 31. Describe how the participant impacted the research agenda. | 17–19 22 24 27–29 33 | 9 16 20 21 23 25 26 30 32–34–36 |
| 32. Describe how the research the research priority setting process impacted the stakeholders. | None | 9 16–36 |
| 33. Describe how impact will be measured. | 26 28 29 | 9 16–25 27 30–36 |
| Funding and conflict of interest | | |
| 34. State sources of funding. | 9 17–25 28 30 31 33 34 36 | 16 26 27 29 32 35 |
| 35. Outline the budget and/or cost. | None | 9 16–36 |
| 36. Provide declaration of conflict of interest. | 9 16 17 19–21 23 24 26 28–31 33–36 | 18 22 25 27 32 |
and whether the research priority setting impacted the participants (online supplemental file 3, figure 3). The completed checklist can be found in Table 3.

### Methods used in paediatric priority setting

Little variation was found in the methods used to involve CYP in paediatric research priority setting. The JLA approach was the most frequently used method (n=16). This was followed by focus groups (n=2), a workshop approach (n=2), the research prioritisation by affected communities (RPAC) method (n=1). The RPAC method directly involves individuals from under-represented groups in identifying, ranking and prioritising their unanswered questions about their health conditions. In one study, different methods were combined (online supplemental file 4, figure 4).

The JLA method divided the involvement of children into four phases. A total of 358 children were involved in the identification of research questions; 287 children were involved in the prioritisation of research questions; 38 children were involved in the prioritisation workshop; and seven children were involved in the steering group (online supplemental file 4, figure 5). To ensure the involvement of paediatric patients of all age categories, Verwoerd and colleagues added focus groups with children in all phases of the JLA method. Similarly, Grant and colleagues organised additional focus groups for younger participants but only at the identification phase. Nonetheless, Lim and colleagues found that focus groups were problematic for the younger participants; therefore, they were contacted individually. The advantages of the JLA were as follows: it is a rigorous method for the establishment of priorities; CYP reported their involvement as positive and powerful; and it fulfils many of the criteria for good practice in priority setting. Examples of the criteria that have been used were using a comprehensive approach and inclusiveness of stakeholders. Disadvantages of the JLA were as follows: prioritisation in this manner is highly subjective; CYP are less represented in almost all phases of the priority setting process; and researchers themselves need to refine the research questions.

Two studies used focus groups to involve CYP. Manikam and colleagues organised two focus groups involving 7–10 CYP. They were asked to prioritise research topics that were submitted by healthcare professionals. Parsons and colleagues organised thirteen focus groups, in which a total of sixty CYP were involved. In these focus groups, CYP were asked to identify the research questions themselves. No advantages or disadvantages were reported using focus groups to involve CYP.

A workshop was used to involve CYP by two research teams. Both teams used the JLA method as a basis for their workshop. Lopez-Vargas and colleagues organised a workshop in which CYP first had to present their prepared research questions and then had to vote for their top three priority questions. Schilstra and colleagues used the workshop to clarify why each priority mattered to the CYP and how they would address the priorities. This approach extended the impact of survey-based approaches by enabling CYP to compare their experiences and actionable research questions were developed. In contrast, survey-based approaches may require less of the CYP’s time than workshops. Furthermore, Schilstra and

### Table 4 Description of focused impact

| Study | Focused impact |
|-------|----------------|
| Knight et al | A number of questions considered during the process were submitted by non-professionals and would not have been considered without their involvement. |
| Verwoerd et al | For both patients and carers, 60% of the questions were selected, for clinicians it was 80%. For the focus groups 2 out of 5 were parts of the final top 10. |
| Lopez-Vargas et al | For children, there was an emphasis for research to help them maintain a sense of normality and to be empowered for self-management and partnership in care. |
| Vella-Baldachchino et al | While the surgeon’s questions focused on the management of specific conditions, the JLA PSP top priorities also included other questions. |
| Grant et al | Many of the questions were similarly ranked across patient/caregiver and clinicians, whereas some had differences in ranks. |
| Fackrell et al | There were notable differences in the interim prioritization between patients and professionals (professionals: effective treatments, patients: causes). |
| Birnie et al | ‘Our involvement of youth and family members led to different identified priorities compared to prior priority setting efforts with no public or youth involvement’. |
| Peeks et al | ‘It is important to note that these priorities did not match those deemed by professionals alone. Professionals prioritized metabolic control, and the role of diet. Patients emphasized the importance of natural progression of disease and complications’. |
| Finer et al | ‘It is notable that the final top 10 research priorities identified in the final workshop differed considerably from those ranked at the interim priority setting’. |

References:

1. Postma L, et al. BMJ Paediatrics Open 2022;6:e001610. doi:10.1136/bmjpo-2022-001610

2. Lopez-Vargas et al. JLA approach was the most frequently used method.

3. Schilstra and colleagues used the workshop to clarify why each priority mattered to the CYP and how they would address the priorities. This approach extended the impact of survey-based approaches by enabling CYP to compare their experiences and actionable research questions were developed.

4. In contrast, survey-based approaches may require less of the CYP’s time than workshops. Furthermore, Schilstra and
colleagues found that recruitment to an in-person workshop can be challenging and time-consuming.34

Another method used to involve CYP was the RPAC.35 Following the RPAC method, two focus groups were organised. In the first focus group, individuals shared their experiences and generated a list of research questions. In the second focus group, individuals prioritised the topics they want researchers to focus on. In both focus groups, 11 CYPs were involved. An advantage of the RPAC is that it was developed to directly involve patients using their personal experiences rather than beginning with survey data.35 No disadvantages were reported.

Reported impact of paediatric priority setting
This study focused on three forms of impact: focused impact, diffuse impact and research impact. Diffuse impact was not described at all.

In nine studies, the focused impact was described.17-19 22 24 27-29 33 Focused impact of the included studies can be divided into two categories: different research questions and different research priorities. In the first category, CYP have different research questions than researchers have. In the second category, CYP have the same research questions, but they prioritised the questions differently than the researchers did (table 4).

Action plans for assessing the research impact were described in three studies26 28 29 (table 5). Noteworthy is that assessing the research impact of research priority setting is as challenging as assessing focused impact. Assessing the research impact takes a long time, and this requires the research team to be involved for a longer time span.

| Study     | Research impact                                                                 |
|-----------|----------------------------------------------------------------------------------|
| Lim et al26 | ‘Assessing the long-term impact of the PSP is important, however measuring and evaluating the impact is challenging and can take a long time’. |
| Peeks et al29 | ‘To both monitor and share information on future research projects that result from these top priorities’. |
| Finer et al28 | ‘The impact of the priority setting partnership on future research investment will be monitored and reported on by Diabetes UK’. |

JLA method most frequently used method
The JLA method was most frequently used to involve CYP in developing a research agenda. van Seventer and colleagues argue that although the outcomes of involving CYP in developing a research agenda have been described, reflecting on the method used to involve CYP is hardly performed.8 Yet, Verwoerd and colleagues did evaluate the JLA method, and they found it to be of added value because otherwise, the views of adolescents and young adults would have been over-represented.38 Our results indicate that only six studies evaluated the method used. Therefore, more information is needed to justify the statement about that JLA method not being well suited to CYP.6

Impact is insufficiently described at best
There is widespread acknowledgement that analysing the focused impact is challenging because it is difficult to know which contribution of the CYP made the difference in developing the research agenda. Yet, this study shows that nine of the included studies attempted to describe the contribution of CYP. It is noteworthy that no studies reported the diffuse impact. The main goal of developing a research agenda together with CYP is to provide the most important research questions. Yet, we should keep in mind that researchers with a positive experience in partnering with CYP in research are most likely to implement a similar collaboration in the future.39 CYP with a positive involvement experience gain knowledge and confidence which can affect their own lives and work and can provide motivation to be involved in later studies.39 Therefore, diffuse impact could also be an important argument for involving CYP.

The JLA recognises that the partnerships between patients, clinicians and professionals may have an impact on the people who participate in them and on the research agenda itself. Interestingly, the JLA guidebook does not elaborate on how to evaluate this impact. The guidebook does provide valuable recommendations on how to maximise the research impact of the agreed priorities.40 The guidebook might have been more all-encompassing if it encouraged
researchers to evaluate the focused and diffuse impact as well.

**Publishing a research agenda should be a tool, not a stand-alone goal**

Only eight of 22 studies reported the action plans to implement the research agenda, and only 3 of these reported keeping track of the research impact. This marginal reporting on the post-prioritisation phase is seen in JLA PSPs in general. As a result, little information is available about whether the research agenda is implemented. Jongsma and colleagues interviewed the participants involved in their PSP. Participants considered the PSP a waste of money and time, should the project end with the publication of the top 10 priorities. This is a striking outcome because our study showed that only a few studies described continuing the project after publishing the research agenda. Staley and colleagues suggested extending the partnership to cover impact-oriented activity beyond publishing the agenda. Taking the results of our study into account, we agree with this proposal so plans can be implemented, and the impact of the research agenda can be measured. Awareness about the fact that publishing the research agenda is not a stand-alone goal is important. Influencing research practice and thereby changing paediatric care should be the goal striving for. Publishing a research agenda is an important tool for achieving that.

**Limitations**

A limitation of this study is the inability to retrieve how many CYP of a specific age group were included. In the included studies, the age of the CYP was divided into broad categories. Although the agendas developed together with children have increased from 4 to 22 in 5 years, we did not compare the number of the research agendas that have been developed together with children to the total of research agendas. Therefore, we cannot state anything about the relative growth compared with the total.

**FUTURE RESEARCH AND CONCLUSION**

This study aimed to identify the methods used to involve CYP in developing a research agenda and to assess what is reported about the impact of involving CYP in research priority setting. We found that the JLA method is most frequently used even though it is rarely evaluated as to whether it is appropriate for involving CYP. This study suggests that an evaluation on the methods should be performed to understand if these are appropriate for the involvement of CYP. Furthermore, this study concludes that reporting the impact remains rare. To be able to measure the impact, researchers should perform a qualitative study focusing on what researchers and CYP believe are important characteristics when measuring the impact of developing a research agenda together. This could lead to an operationalised definition of impact. In our follow-up study, we will start with this. Furthermore, we recommend expanding the guidelines on involving children in developing a research agenda with information on how to evaluate the impact.

**Acknowledgements**

We thank T van Wulffen Palthe, PhD, for correcting the English manuscript.

**Contributors**

LP coordinated this project, collected and analysed the data, wrote the first version of the manuscript, and drafted and wrote the final version of the manuscript. EM was involved in data collection, analysis and drafting the manuscript. EV and ML were involved in drafting the manuscript and writing the final version of the manuscript.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

None declared.

**Patient consent for publication**

Not applicable.

**Ethics approval**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Laura Postma http://orcid.org/0000-0002-3199-7179

**REFERENCES**

1. Gray-Burrows KA, Willis TA, Foy R, et al. Role of patient and public involvement in implementation research: a consensus study. BMJ Qual Saf 2018;27:858–64.
2. ZonMW. Procedure voor Aanvragers; 2019.
3. Chalmers I, Glasziou P, et al. Avoidable waste in the production and reporting of research evidence. The Lancet 2009;374:86–9.
4. Chalmers I, Atkinson P, Fenton M, et al. Tackling treatment uncertainties together: the evolution of the James Lind Initiative, 2003–2013. J R Soc Med 2013;106:482–91.
5. Morris C, Simikias D, Busk M, et al. Setting research priorities to improve the health of children and young people with neurodisability: a British Academy of childhood disability-James Lind Alliance research priority setting partnership. BMJ Open 2015;5:e006233.
6. Odgers HL, Tong A, Lopez-Vargas P, et al. Research priority setting in childhood chronic disease: a systematic review. Arch Dis Child 2018;103:942–51.
7. McDonagh JE, Bateman B. ‘Nothing about us without us’: considerations for research involving young people. Arch Dis Child Educ Pract Ed 2012;97:55–60.
8. Jongsma K, van Seventer J, Verwoerd A, et al. Recommendations from a James Lind Alliance Priority Setting Partnership - a qualitative interview study. Res Involv Engagem 2020;6:68.
9. Parsons S, Thomson W, Creswell K, et al. What do young people with rheumatic disease believe to be important to research about their condition? A UK-wide study. Pediatr Rheumatol Online J 2017;15:33.
10. Crocker JC, Boylan A-M, Bostock J, et al. Is it worth it? patient and public views on the impact of their involvement in health research.
and its assessment: a UK-based qualitative interview study. Health Expect 2017;20:519–28.
11 van Schellen F, Groenewegen P, Spreeuwenberg P, et al. Exploring the impact of patient and public involvement with young people with a rare genetic condition: a multilevel analysis. Child Care Health Dev 2021;47:349–56.
12 Mockford C, Staniszewska S, Griffiths F, et al. The impact of patient and public involvement on UK NHS health care: a systematic review. Int J Qual Health Care 2012;24:28–38.
13 Dudley L, Gambale C, Preston J, et al. What difference does patient and public involvement make and what are its pathways to impact? qualitative study of patients and researchers from a cohort of randomised clinical trials. PLoS One 2015;10:e0128817.
14 Staniszewska S, Brett J, Simera I, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. Res Involv Engagem 2017;3:13.
15 Flynn R, Walton S, Scott SD. Engaging children and families in pediatric health research: a scoping review. Res Involv Engagem 2019;5:32.
16 Obed N, McVeigh G, Seale E, et al. Cocreating research priorities for anorexia nervosa: the Canadian eating disorder priority setting partnership. Int J Eat Disord 2020;53:862–72.
17 Verwoerd A, Armbrust W, Cowan K, et al. Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritis. Pediat Rheumatol Online J 2021;19:52.
18 Grant A, Crane M, Laupacis A, et al. Engaging patients and caregivers in research for pediatric inflammatory bowel disease: top priorities. J Pediat Gastroenterol Nutr 2019;69:317–23.
19 Fackrell K, Stratmann L, Kennedy V, et al. Identifying and prioritising unanswered research questions for people with hyperacusis: James Lind alliance hyperacusis priority setting partnership. BMJ Open 2019;9:e032178.
20 Morris RL, Stocks SJ, Alam R, et al. Identifying primary care patient safety research priorities in the UK: a James Lind alliance priority setting partnership. BMJ Open 2018;8:e020870.
21 Rankin G, Summers R, Cowan K, et al. Identifying priorities for physiotherapy research in the UK: the James Lind alliance physiotherapy priority setting partnership. Physiotherapy 2020;107:161–8.
22 Birnie KA, Dib K, Ouellette C, et al. Partnering for pain: a priority setting partnership to identify patient-oriented research priorities for pediatric chronic pain in Canada. CMAJ Open 2019;7:E654–64.
23 Aldiss S, Fern LA, Phillips RS, et al. Research priorities for young people with cancer: a UK priority setting partnership with the James Lind alliance. BMJ Open 2019;9:e028119.
24 Vella-Baldacchino M, Perry DC, Roposch A, et al. Research priorities in children requiring elective surgery for conditions affecting the lower limbs: a James Lind alliance priority setting partnership. BMJ Open 2019;9:e033233.
25 Lam JR, Liu B, Bhatre R, et al. Research priorities for the future health of multiples and their families: the global twins and multiples priority setting partnership. Ultrasound Obstet Gynecol 2019;54:715–21.
26 Lim AK, Rhodes S, Cowan K, et al. Joint production of research priorities to improve the lives of those with childhood onset conditions that impair learning: the James Lind alliance priority setting partnership for ‘learning difficulties’. BMJ Open 2019;20:032890.
27 Knight SR, Metcalfe L, O’Donoghue K, et al. Defining priorities for future research: results of the UK kidney transplant priority setting partnership. PLoS One 2016;11:e0162138.
28 Finer S, Robb P, Cowan K, et al. Setting the top 10 research priorities to improve the health of people with type 2 diabetes UK-James Lind alliance priority setting partnership. Diabet Med 2018;35:862–70.
29 Peeks F, Boonstra WF, de Baere L. Research priorities for liver glycogen storage disease: an international priority setting partnership with the James Lind alliance. J Inherit Metab Dis 2019;43:279–89.
30 Ismail D, McAteer H, Majeed-Aris S, et al. Research priorities and identification of a health-service delivery model for psoriasis from the UK psoriasis priority setting partnership. Clin Exp Dermatol 2021;46:276–85.
31 Hollis C, Sampson S, Simons L, et al. Identifying research priorities for digital technology in mental health care: results of the James Lind alliance priority setting partnership. Lancet Psychiatry 2018;5:845–54.
32 Manikam L, Shah R, Reed K, et al. Using a co-production prioritization exercise involving South Asian children, young people and their families to identify health priorities requiring further research and public awareness. Health Expectations 2020;23:502–11.
33 Lopez-Vargas P, Tong A, Crowe S, et al. Research priorities for childhood chronic conditions: a workshop report. Arch Dis Child 2018;103:237–45.
34 Schilstra CE, Sansom-Daly UM, Schaffer M, et al. "We Have All This Knowledge to Give, So Use Us as a Resource": Partnering with Adolescent and Young Adult Cancer Survivors to Determine Consumer-Led Research Priorities. J Adolesc Young Adult Oncol 2022;11:21–22.
35 von Schellen E, Nahal BK, Cohen IG, et al. Research questions that matter to us: priorities of young people with chronic illnesses and their caregivers. Pediatr Res 2020;89:1659–63.
36 Shattuck PT, Lau L, Anderson KA, et al. A national research agenda for the transition of youth with autism. Pediatrics 2018;141:S355.
37 Viergever RF, Olffson S, Ghaffar A, et al. A checklist for health research priority setting: nine common themes of good practice. Health Res Policy Syst 2010;8:36.
38 Aussem K, Schoemaker CG, Verwoerd A, et al. Research agenda setting with children with juvenile idiopathic arthritis: lessons learned. Child Care Health Dev 2022;48:68–79.
39 Staley K, Crowe S, Crocker JC, et al. What happens after James Lind alliance priority setting partnerships? A qualitative study of contexts, processes and impacts. Res Involv Engagem 2020;6:1–41.
40 The James Lind alliance Guidebook, 2021 -03